Active Ingredient History
Prazosin (trade names Minipress, Vasoflex, Lentopres, and Hypovase) is a selective α-1-adrenergic receptor antagonist used to treat hypertension. Prazosin acts by inhibiting the postsynaptic alpha-1-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases. The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure. Prazosin is also useful in treating urinary hesitancy associated with prostatic hyperplasia, blocking alpha-1 receptors, which control constriction of both the prostate and urethra. Although not a first line choice for either hypertension or prostatic hyperplasia, it is a choice for patients who present with both problems concomitantly. Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea. Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, nervousness, and rash. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertension (approved 1976)
Alcoholism (Phase 4)
Alcohol Withdrawal Delirium (Phase 2)
Alzheimer Disease (Phase 2)
Anxiety (Phase 1)
Anxiety Disorders (Phase 1)
Atherosclerosis (Phase 4)
Blood Pressure (Phase 2)
Brain Concussion (Phase 1/Phase 2)
Cannabis (Phase 4)
Cardiovascular Diseases (Phase 1)
Cigarette Smoking (Early Phase 1)
Combat Disorders (Phase 1/Phase 2)
COVID-19 (Phase 2)
Dementia (Phase 4)
Dreams (Phase 4)
Fibrosis (Phase 4)
Gastrointestinal Hemorrhage (Phase 4)
Headache (Phase 2)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 1)
Hepatitis C, Chronic (Phase 2)
Hypertension (Phase 4)
Hypertension, Portal (Phase 4)
Kidney Calculi (Phase 3)
Marijuana Abuse (Phase 4)
Methamphetamine (Phase 2)
Migraine Disorders (Phase 2)
Nicotine (Phase 1)
Pheochromocytoma (Phase 2)
Post-Concussion Syndrome (Phase 1/Phase 2)
Post-Traumatic Headache (Phase 4)
Problem Behavior (Phase 2)
Prostatic Hyperplasia (Phase 4)
Rhinitis (Phase 4)
Rhinitis, Allergic (Phase 4)
Scorpion Stings (Phase 3)
Sleep Wake Disorders (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Stress Disorders, Traumatic, Acute (Phase 2)
Stress, Psychological (Phase 2)
Suicidal Ideation (Phase 4)
Tachyphylaxis (Phase 4)
Tobacco Use Disorder (Phase 2)
Urinary Bladder, Neurogenic (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
